Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saktimayee M Roy

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Bioorganic & Medicinal Chemistry Letters|November 3, 2006
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficitsWenhui Hu, Hantamalala Ralay Ranaivo, Saktimayee M Roy, et al.
International Journal of Molecular Sciences|May 1, 2019
Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of CancerAmreena Suri, Anders W Bailey, Maurício T Tavares, et al.
Brain, Behavior, & Immunity - Health|August 20, 2024
A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologiesHilaree N Frazier, David J Braun, Caleb S Bailey, et al.
Clinical Pharmacology in Drug Development|April 8, 2020
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult VolunteersLinda J Van Eldik, Lumy Sawaki, Karen Bowen, et al.
ACS Chemical Neuroscience|February 14, 2015
Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse modelsSaktimayee M Roy, Valerie L Grum-Tokars, James P Schavocky, et al.
Plos One|July 11, 2013
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionD Martin Watterson, Valerie L Grum-Tokars, Saktimayee M Roy, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Bioorganic & Medicinal Chemistry Letters|November 3, 2006
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficitsWenhui Hu, Hantamalala Ralay Ranaivo, Saktimayee M Roy, et al.
International Journal of Molecular Sciences|May 1, 2019
Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of CancerAmreena Suri, Anders W Bailey, Maurício T Tavares, et al.
Brain, Behavior, & Immunity - Health|August 20, 2024
A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologiesHilaree N Frazier, David J Braun, Caleb S Bailey, et al.
Clinical Pharmacology in Drug Development|April 8, 2020
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult VolunteersLinda J Van Eldik, Lumy Sawaki, Karen Bowen, et al.
ACS Chemical Neuroscience|February 14, 2015
Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse modelsSaktimayee M Roy, Valerie L Grum-Tokars, James P Schavocky, et al.
Plos One|July 11, 2013
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionD Martin Watterson, Valerie L Grum-Tokars, Saktimayee M Roy, et al.
Pageof 2